Skip to main
CLBT

CLBT Stock Forecast & Price Target

CLBT Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Cellebrite DI is poised for continued success, with a solid financial performance and a strong focus on expansion and innovation. However, potential risks and challenges must be carefully monitored to ensure sustained growth. Their success will also depend on their ability to effectively capitalize on cross-selling and upselling opportunities to existing customers. The pending acquisition of Corellium also presents potential for further growth and diversification in their offerings.

Bears say

Cellebrite DI is a purpose-built DI platform that is facing an intense market with many competitors, and any increase in competition could result in pricing pressure and market share loss. Additionally, the company also faces the risk of perception as a violation of privacy rights or human rights, which could impact its market opportunity. Other risks include fluctuations in foreign currency, extended sales cycles, and the potential for a breach of its solutions and data. Despite success in ARR and adjusted EBITDA in the past quarter, the company may still face challenges in meeting its margin outlook and could be impacted by a stock market correction.

CLBT has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Cellebrite DI Ltd and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Cellebrite DI Ltd (CLBT) Forecast

Analysts have given CLBT a Strong Buy based on their latest research and market trends.

According to 4 analysts, CLBT has a Strong Buy consensus rating as of Apr 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $22.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $22.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Cellebrite DI Ltd (CLBT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.